Navigation Links
Vermillion to Report Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013
Date:2/19/2013

AUSTIN, Texas, Feb. 19, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a molecular diagnostics company focused on gynecologic cancers and vascular medicine, will hold a conference call on Wednesday, February 20, 2013, at 4:30 p.m. ET to discuss full results for its fourth quarter and year ended December 31, 2012.

While previously expecting to report only preliminary results on this date, the company recently received its annual 'true-up' of OVA1 sales from Quest Diagnostics ahead of schedule. This will allow for complete 2012 results to be issued in a press release prior to the call.

Vermillion's interim CEO Bruce A. Huebner will host the call, followed by a question and answer period.

Date: Wednesday, February 20, 2013
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-In Number: 1-800-909-4761
International: 1-212-231-2934
Conference ID#: 21648726
Webcast: http://edge.media-server.com/m/p/e247e2q2/lan/en

The conference call will be webcast live and available for replay via the investor section of the company's website at www.vermillion.com.

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.

A replay of the call will be available approximately two hours after the call through March 6, 2013.

Toll-free replay number: 1-800-633-8284
International replay number: 1-402-977-9140
Replay pin number: 21648726

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, vascular medicine and women's health. Additional information about Vermillion can be found at www.vermillion.com.

Investor Relations Contact:
Liolios Group, Inc.
Ron Both
Tel 1-949-574-3860
vrml@liolios.com


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion Sharpens Focus and Streamlines Operations in 2012
2. Vermillion Reports Fourth Quarter and Full Year 2011 Results
3. Vermillion Reports First Quarter 2012 Results
4. Concerned Stockholders Launch Save Vermillion! Website: www.savevrml.com
5. Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013
6. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... Corista, a ... and artificial intelligence Tuesday, July 25, during the Association of Pathology Chairs’ Jubilee ... Medicine. , Baras, Associate Director of Pathology Informatics, will present “The Digital ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... to make clinical trial sites and study participants truly unified. TrialKit, a native ... (FDA 21 CFR Part 11) research studies entirely on mobile devices. With TrialKit, ...
(Date:7/18/2017)... ... 18, 2017 , ... Genedata, a leading provider of advanced ... company, has implemented Genedata Biologics ™ to scale-up their bispecific antibody discovery ... Neurodegenerative Diseases. , The need to systematically evaluate large panels of multi-specific ...
(Date:7/18/2017)... ... July 18, 2017 , ... Allotrope ... released the first phase of the Allotrope Framework for commercial use. , The ... created to “not only elevate the critical role of information technology in modern ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
Breaking Biology News(10 mins):